» Authors » Long Shan Li

Long Shan Li

Explore the profile of Long Shan Li including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 426
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Huffman K, Li L, Carstens R, Park H, Girard L, Avila K, et al.
Front Oncol . 2023 Apr; 13:1025443. PMID: 37035141
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemotherapy regimens...
2.
Yenerall P, Das A, Wang S, Kollipara R, Li L, Villalobos P, et al.
Cell Chem Biol . 2019 Dec; 27(1):105-121.e14. PMID: 31883965
RUVBL1 and RUVBL2 (collectively RUVBL1/2) are essential AAA+ ATPases that function as co-chaperones and have been implicated in cancer. Here we investigated the molecular and phenotypic role of RUVBL1/2 ATPase...
3.
Deb D, Rajaram S, Larsen J, Dospoy P, Marullo R, Li L, et al.
Cancer Res . 2017 Apr; 77(11):3070-3081. PMID: 28377453
Oncogene-specific changes in cellular signaling have been widely observed in lung cancer. Here, we investigated how these alterations could affect signaling heterogeneity and suggest novel therapeutic strategies. We compared signaling...
4.
Cao L, Li L, Spruell C, Xiao L, Chakrabarti G, Bey E, et al.
Antioxid Redox Signal . 2014 Feb; 21(2):237-50. PMID: 24512128
Aims: β-Lapachone (β-lap), a novel radiosensitizer with potent antitumor efficacy alone, selectively kills solid cancers that over-express Nad(p)h: quinone oxidoreductase 1 (NQO1). Since breast or other solid cancers have heterogeneous...
5.
Bey E, Reinicke K, Srougi M, Varnes M, Anderson V, Pink J, et al.
Mol Cancer Ther . 2013 Jul; 12(10):2110-20. PMID: 23883585
Improving patient outcome by personalized therapy involves a thorough understanding of an agent's mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the...
6.
Kim H, Rigell C, Zhai G, Lee S, Samuel S, Martin A, et al.
Mol Imaging Biol . 2013 Jul; 16(1):85-94. PMID: 23836505
Purpose: To examine the antagonistic effects of anti-extracellular matrix metalloprotease inducer (anti-EMMPRIN) antibody when combined with chemotherapy using a hypovascular pancreatic tumor model. Procedures: Severely compromised immunodeficient mice bearing orthotopic...
7.
Li L, Bey E, Dong Y, Meng J, Patra B, Yan J, et al.
Clin Cancer Res . 2011 Jan; 17(2):275-85. PMID: 21224367
Purpose: Pancreatic cancer is the fourth leading cause of cancer-related deaths, in which the 5-year survival rate is less than 5%. Current standard of care therapies offer little selectivity and...
8.
Li L, Morales J, Veigl M, Sedwick D, Greer S, Meyers M, et al.
Br J Pharmacol . 2009 Sep; 158(3):679-92. PMID: 19775280
The metabolism and efficacy of 5-fluorouracil (FUra) and other fluorinated pyrimidine (FP) derivatives have been intensively investigated for over fifty years. FUra and its antimetabolites can be incorporated at RNA-...
9.
Wagner M, Li L, Morales J, Galindo C, Garner H, Bornmann W, et al.
J Biol Chem . 2008 May; 283(31):21382-93. PMID: 18480061
Current published data suggest that DNA mismatch repair (MMR) triggers prolonged G(2) cell cycle checkpoint arrest after alkylation damage from N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) by activating ATR (ataxia telangiectasia-Rad3-related kinase). However, analyses...
10.
Li L, Morales J, Hwang A, Wagner M, Boothman D
J Biol Chem . 2008 May; 283(31):21394-403. PMID: 18480060
Cells with functional DNA mismatch repair (MMR) stimulate G(2) cell cycle checkpoint arrest and apoptosis in response to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). MMR-deficient cells fail to detect MNNG-induced DNA damage, resulting in...